Office of Technology Management
Department of Pediatrics
The Office of Technology Management

Startups

 


The newly established Biotechnology Commercialization Center (BCC), located in the University Center Tower (UCT) at UTHSC-H, is available for new startup companies. The BCC’s mission is to help commercialize and incubate UTHSC-H and Houston-based technologies, while increasing the number of Texas-based companies. Located within the heart of the Texas Medical Center, the BCC provides valuable access to information, collaboration and expertise.

Ammenities include:

• Approximately 20,000 sq. ft of combined laboratory, office, and shared areas on three adjacent floors in UCT dedicated to startup companies
• Access to UTHSC-H core laboratory and animal services as well as capital equipment
• Conference and meeting spaces
• Shared building services
• Onsite Parking

 

 

 

 

 


Current Tenants

 

 


Aviara Pharmaceutical Research

Aviara is a startup pharmaceutical research and development company with a mission of providing medicinal chemistry services for the translation of novel chemical lead molecules into commercially relevant pharmaceuticals.

 


Bissex & Watson, P.C.

Bissex & Watson is a boutique law firm representing universities, companies, entrepreneurs, and investors in the commercialization of technology. The firm contributes to the success of its clients in a wide range of transactions, such as capital raising, mergers and acquisitions, and providing general counsel advice on day-to-day matters. Members of the firm have both "big firm" experience and experience as general counsel of public companies, and they have experience starting and operating their own businesses.

 


CASIS

The Center for the Advancement of Science in Space (CASIS), is a nonprofit organization selected by NASA in the summer of 2011, to manage the International Space Station (ISS) U.S. National Laboratory. CASIS serves as the entryway to accessing the low-Earth orbit environment of the ISS U.S. National Lab and to joining a diverse and dynamic community of researchers, innovators and educators who seek discoveries that will take us beyond the current thresholds of science, engineering, technology and education to create a more vibrant and thriving future for citizens of the world..

 


Colibri Heart Valve, LLC

Colibri is a medical device company started by two physicians at St. Luke’s Episcopal Hospital to develop medical devices for implantation into the heart and vascular system. Colibri’s initial device is a novel heart valve implanted by catheter.

 


CorInnova, Inc.

CorInnova is a medical device company currently engaged in the development of revolutionary and innovative technologies that enhance heart recovery through the restoration of necessary mechanical stimuli. The minimally invasive technology promises to restore motion necessary for heart rehabilitation.

 


Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. is focused on the use of fullerene carbon nanotubes as delivery agents for cancer therapeutics. Carbon nanotubes' unique chemical structure allows them to form stable complexes with cancer-cell targeted agents ranging from small interfering RNA (siRNA) to currently existing cancer drugs such as taxol and doxorubicin. Carbon nanotube complexes can carry these active agents into cancer cells as payloads, protecting them during transport, and, importantly, releasing the payload once inside the cancer cells. All of these features make carbon nanotubes ideal for use with many active macromolecules.


Leonardo Biosystems

Leonardo Biosystems, Inc.

Leonardo Biosystems uses multi-stage nanovector drug delivery technology, based on research by UTHSC-H’s Dr. Mauro Ferrari and colleagues, to facilitate chemotherapy and biological anti-cancer agent delivery. The company’s first target market is refractory breast cancer.

 

 

Nano3D Biosciences, Inc.

Nano3D Biosciences, Inc. (n3D) seeks to create the industry leading standard for 3-dimensional cell culturing solutions. Using a proprietary combination of nanoparticle-based reagents and magnetic fields, n3D created a simple device to magnetically levitate cells to enable 3-dimensional tissue growth. n3D’s “Bio-Assembler” succeeds in offering an in vitro device that mimics the in vivo environment with many major advantages over existing cell culturing methods. This breakthrough technology will directly address core needs in life sciences, drug discovery, toxicology, and regenerative medicine.

 


PHusis Therapeutics, Inc.

Phusis Therapeutics, in collaboration with M.D. Anderson, is developing novel cancer agents, targeting the PH domain of high value cancer drug targets.

 

 

 

For information on available space, please contact Bruce Butler or Christine Flynn.